A subcutaneous abscess following anti‐programmed cell death 1/programmed death‐ligand 1 antibody treatment for lung cancer

Abstract

Immune checkpoint inhibitor targeted programmed cell death 1/programmed death‐ligand 1 or CTLA4 develops immune cell‐mediated anti‐cancer treatment showing a beneficial impact on the clinical outcomes. On the other hand, these treatments sometimes enhance an undesirable immunological adverse reaction to various organs. Herein, we experienced a case of subcutaneous abscess located in the previously received appendectomy following atezolizumab for lung cancer.